Evidence map›Paper›PMID 26080370›Full record

Trial reportThe Journal of infectious diseases2015

Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants.

Marta C Nunes, Clare L Cutland, Bonnie Dighero, Janie Bate, Stephanie Jones, Andrea Hugo, Nadia van Niekerk, Locadiah Kuwanda, Alane Izu, Adriana Weinberg and 2 more

Erratum issuedOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Marta C NunesVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Clare L CutlandVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Bonnie DigheroDepartment of Pediatrics, University of Colorado, Aurora Department of Medicine, University of Colorado, Aurora Department of Pathology, University of Colorado, Aurora.
Janie BateDepartment of Pediatrics, University of Colorado, Aurora Department of Medicine, University of Colorado, Aurora Department of Pathology, University of Colorado, Aurora.
Stephanie JonesVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Andrea HugoVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Nadia van NiekerkVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Locadiah KuwandaVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Alane IzuVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand.
Adriana WeinbergDepartment of Pediatrics, University of Colorado, Aurora Department of Medicine, University of Colorado, Aurora Department of Pathology, University of Colorado, Aurora.
Shabir A MadhiVaccine Preventable Diseases Unit, Department of Science and Technology, National Research Foundation Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of the Witwatersrand National Institute for Communicable Diseases, National Health Laboratory Service, Centre for Vaccines and Immunology, Johannesburg, South Africa.
Matflu Team
National Research Foundation · ZARespiratory and Meningeal Pathogens Research Unit · ZAUniversity of Colorado Denver · USMedical Research Council · GBUniversity of Colorado Anschutz Medical Campus · USUniversity of the Witwatersrand · ZA

Funding

Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
NCATS NIH HHS UL1 TR000154
6 · The paper itself

Abstract

backgroundWe evaluated the immunogenicity of trivalent inactivated influenza vaccine (IIV3) in pregnant women with and those without human immunodeficiency virus (HIV) infection and the persistence of hemagglutination-inhibiting antibodies in mothers and infants.

methodsAntibodies were measured before vaccination, 1 month after vaccination, at delivery, and at postpartum week 24 in mothers and within 1 week of birth and at 8, 16, and 24 weeks of age in infants.

resultsWe enrolled 98 HIV-uninfected and 100 HIV-infected pregnant women, including 93% with a CD4(+) T-cell count of ≥ 200 cells/µL. Compared with HIV-uninfected women, HIV-infected women had lower seroconversion rates (ranging from 63%-92% vs 36%-40%), lower antibody titers through postpartum week 24, and overlapping antibody half-lives (ranging from 106-121 vs 87-153 days). Infant titers were lower than the maternal titers within 1 week of delivery, regardless of vaccine strain and HIV exposure status. Compared with HIV-unexposed infants, HIV-exposed infants had a similar transplacental influenza virus antibody transfer ratio, lower titers, and a lower frequency of titers ≥ 1:40 (ranging from 82%-95% vs 43%-79%) at birth and higher antibody half-lives (ranging from 43-45 vs 56-65 days).

conclusionsCompared with HIV-uninfected pregnant women, HIV-infected pregnant women had lower antibody responses and persistence. Compared with HIV-unexposed infants, HIV-exposed infants had lower antibody levels at birth but similar antibody levels after 8 weeks of life. Early IIV3 administration during pregnancy did not decrease antibody titers among infants at birth.

Indexed as

AdultAntibodies, ViralCohort StudiesFemaleHemagglutination Inhibition TestsHIV InfectionsHumansInfantInfant, NewbornInfluenza, HumanInfluenza VaccinesMalePregnancyPregnancy Complications, InfectiousVaccines, InactivatedYoung AdultAntibodies, ViralInfluenza VaccinesVaccines, InactivatedHIVimmunogenicityinfluenza vaccinepregnancytransplacental antibody transfer

Identifiers

PMID26080370
PMCPMC4655859
OpenAlexW2275031738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.